MANCHESTER, Conn, Jan. 26, 2012 (CRWENEWSWIRE) — Charter Medical, Ltd., a Lydall, Inc. subsidiary, (NYSE:LDL) announced today that it received CE Mark approval on its next generation Cell Freeze(R) Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPC’s). The issuance of the approval by European regulators allows Charter Medical to begin marketing and selling the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPC’s in Europe. These next generation storage containers offer a broad size range from 50 mL to 750 mL and have excellent durability when frozen at ultralow (-196*C) temperatures.

Joe Petrosky, Vice President of Global Marketing and Sales for Charter Medical, stated: “We are excited at this launch of the Cell-Freeze(R) product family of cryogenic storage containers into Europe. These products serve several high growth markets including cellular therapy and have already received acceptance at several customers in the U.S.”

Dale Barnhart, CEO of Lydall, stated: “I am pleased with the launch of this product into Europe which represents a strategic growth opportunity for the Cell-Freeze(R) product line. It demonstrates our commitment to increase our presence globally in the biotech and cellular therapy markets.”

About Lydall, Inc.

Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, the Netherlands and Germany and offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets. Charter Medical, Ltd., a Lydall subsidiary, is a vital fluids management company focused on providing products to separate, contain and transport vital fluids in the blood and cell therapy market and the biotech and pharmaceutical industries. Lydall(R) is a registered trademark of Lydall, Inc. in the U.S. and other countries. All product names are trademarks of Lydall, Inc. or Charter Medical, Ltd.

Source: Lydall, Inc.

Contact:

For further Charter Medical Information:
Dominic Clarke, Ph.D.
Product Manager
Cellular Therapy and Cryogenic Storage
3948-A Westpoint Blvd.
Winston-Salem, NC 27103
Phone: (336) 768-6447
Fax: (336) 774-1750
dclarke@lydall.com
www.chartermedical.com
Erika G. Turner
Vice President, Chief Financial Officer
and Treasurer
Telephone 860.646.1233
Facsimile 860.646.8847
www.lydall.com
info@lydall.com

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.